HomeNewsIndiaIndia battles supply snags in race to build affordable ventilators

India battles supply snags in race to build affordable ventilators

Ventilators help patients breathe and are seen as critical given severe COVID-19 can lead to pneumonia and lung damage.

April 22, 2020 / 16:18 IST
Representative image

Indian medical device makers, racing to churn out ventilators as domestic COVID-19 cases spike, have been beset by supply bottlenecks, cost overruns and labour shortages that are delaying their efforts to produce an affordable device.

Ventilators help patients breathe and are seen as critical given severe COVID-19 can lead to pneumonia and lung damage. Experts warn India may run out of devices as it has fewer than 50,000 and may need 20 times that in a peak infection scenario.

Companies, including Bengaluru-based Dynamatic, startup Nocca Robotics and New Delhi's AgVa Healthcare, are rushing to fill the expected supply gap with stripped-down ventilators, priced between $33 and $7,000.

Top-end ventilators can cost up to $16,000 in India.

But with many countries boosting output and India forced into a lockdown, components and labour are in short supply, leading to production delays of up to two weeks.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"We require components that are extremely hard to procure," said Amitabha Bandyopadhyay, a professor at the Indian Institute of Technology, Kanpur, who is collaborating with Nocca.

Nocca has been set back by two weeks and now aims to make 30,000 ventilators by mid-May, as it struggles to import high-capacity pumps and flow sensors that help regulate air in ventilators, Bandyopadhyay added.

"These materials are so rare now in the international market that there has been a 50 percent-75 percent increase in prices in the last one month," he said. This has doubled the estimated price of Nocca's devices to 150,000 rupees ($1,950).

Nocca is in talks with several large manufacturers to start production once its prototypes clear tests by early May.

Most Indian medical device executives said they were making ventilators for domestic use. Bandyopadhyay said exports would depend on government curbs and economic viability.

COSTS SKYROCKET

India has ordered its 1.3 billion people indoors until May 3 so its modest public health system does not collapse under the weight of infections that are nearing 19,000. Over 600 people have died due to the coronavirus in the country.

Most of those numbers are from this month.

"If 10 percent of our population is infected and only 1 percent of them need ventilators, even then we are way behind," said Subhrojyoti Bhowmick, clinical director, academics and research department, at Peerless Hospital in the eastern city of Kolkata.

Before the pandemic, hospitals invested less in ventilators as they are expensive and the devices were available mainly in some hospitals in bigger Indian cities, Bhowmick added.

But companies are now pushing to make affordable devices.

Dynamatic Technologies is making a $33 ventilator that does not need electricity to function, while AgVa is aiming to make 10,000 ventilators by mid-May, priced under $2,000.

AgVa is collaborating with automaker Maruti Suzuki and state-run Bharat Electronics to make parts.

But it is facing labour shortages and higher costs as it sources controllers and microprocessors from Germany, the United States and China, AgVa co-founder Diwakar Vaish said.

"The overall costs have ... doubled, maybe even tripled," prompting AgVa to rope in five or six suppliers for some components from just two or three earlier, Vaish said.

LOCKDOWN: SERIOUS DISABLER

To speed up production, India's government is helping with sourcing components and easing bottlenecks. State-run HLL Lifecare Ltd has floated a tender to procure 20,000 ventilators.

India's drugs regulator has also allowed firms to make ventilators without a manufacturing licence, according to an email from the agency's chief seen by Reuters.

Defence Research and Development Organisation (DRDO), a government agency, is collaborating with Skanray, a medical device player based in the southern city of Mysuru.

DRDO is making on a "war footing" components such as sensors that are typically imported to aid ventilator production, Skanray Managing Director Vishwaprasad Alva said.

Skanray ventilators cost around $7,000.

But for manufacturers, "the lockdown is a serious disabler", Dynamatic CEO Udayant Malhoutra said. "The challenge is huge, because the whole ecosystem of suppliers is shut down."

Supply issues are causing a delay of 3-4 days in the 30-day manufacturing cycle, he said. "In a 10-month development cycle, that means you are off by a month."

Follow our full coverage of the coronavirus pandemic here.

Reuters
first published: Apr 22, 2020 04:10 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347
CloseOutskill Genai